Absorption |
Gastric acidity |
| Antacids | Separate administration times by at least 2 h (26), (27) |
H2-receptor antagonists |
|
Proton pump inhibitors | Avoid concomitant use |
Chelation |
Dolutegravir Elvitegravir Raltegravir
| Antacids | Separate administration times by at least 2 h (28)– (30) |
Metabolism |
CYP450 3A4 |
|
Fentanyl, oxycodone Anticonvulsants (e.g., carbamazepine, phenytoin) Antiplatelet agents Anticoagulants Calcium-channel blockers (e.g., amlodipine, diltiazem, nifedipine, verapamil) Corticosteroids (e.g., inhaled fluticasone–budesonide, triamcinolone by injection) Phosphodiesterase inhibitors Psychotropics (e.g., aripiprazole, quetiapine, ziprasidone) Statins (e.g., lovastatin, simvastatin)
|
Concentrations of coadministered agents may be increased or decreased Consider agents less likely to interact Monitor patient’s response and adjust dose of coadministered agent accordingly
|
Other CYP450 isoenzymes (e.g., CYP2D6, CYP2B6, CYP2C9, CYP2C19) |
|
|
Concentrations of coadministered agents may be increased or decreased Consider agents less likely to interact Monitor patient’s response and adjust dose of coadministered agent
|